Source: AMA Morning Rounds 3/29/2010
Monday, March 29, 2010
More hospitals offering therapeutic hypothermia for comatose survivors of cardiac arrest
Source: AMA Morning Rounds 3/29/2010
Sunday, March 21, 2010
Oral contraceptives may reduce risk of death from any cause in women.
Source: AMA Morning Rounds 3/12/2010, BMJ Press Release 3/12/2010
(4) Contraceptive pill not associated with increased long-term risk of death
(Research: Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study)
http://www.bmj.com/cgi/
Women in the UK who have ever used the oral contraceptive pill are less likely to die from any cause, including all cancers and heart disease, compared with never users, according to research published on bmj.com today.
The results show a slightly higher risk in women under 45 years old who are current or recent users of the pill. The authors stress that the effects in younger women disappear after about 10 years. Furthermore, the benefits in older women outweigh the smaller excess risks among younger women.
The study continues to find a higher rate of violent or accidental death among oral contraceptive users compared with never users. The authors are unable to explain this persistent finding.
In May 1968, the Royal College of General Practitioners' (RCGP) began the RCGP Oral Contraception Study, one of the world’s largest continuing investigations into the health effects of oral contraceptives.
Early reports from the RCGP study suggested an increased risk of death among oral contraceptive users, mainly due to an excess of strokes or other vascular problems among older women or those who smoked. Although a later report suggested that these effects disappear once the pill is stopped, at the time there were relatively few cases of different types of cancer.
These latest results, led by Professor Philip Hannaford from the University of Aberdeen, relate to the 46,000 recruited women, followed for up to nearly 40 years, creating more than a million woman-years of observation.
The results show that in the longer term, women who used oral contraception had a significantly lower rate of death from any cause, including heart disease and all cancers (notably bowel, uterine body and ovarian cancers) compared with never users.
This equates to 52 fewer deaths per 100,000 woman-years.
Slightly higher rates were found among younger women who had used oral contraception, with 20 more deaths per 100,000 among those younger than 30, and four more deaths per 100,000 among 30-39 year olds.
But by the age of 50, the benefits outweighed these modest risks, with 14 fewer deaths per 100,000 among 40-49 year olds; 86 fewer deaths per 100,000 for 50-59 year olds; 122 fewer deaths per 100,000 for 60-69 year olds; and 308 fewer deaths per 100,000 for 70+ year olds.
Hannaford says: "Many women, especially those who used the first generation of oral contraceptives many years ago, are likely to be reassured by our results. However, our findings might not reflect the experience of women using oral contraceptives today, if currently available preparations have a different risk than earlier products."
The authors conclude that their results, derived from a relatively healthy UK study group, show that "oral contraception is not significantly associated with an increased long-term risk of death . . . indeed a net benefit was apparent." However, they point out that "the balance of risks and benefits may vary globally, depending upon patterns of oral contraception usage and background risk of disease."
Contact:
Philip Hannaford, Centre of Academic Primary Care, University of Aberdeen, Scotland
Email p.hannaford@abdn.ac.uk
Oral contraceptives may reduce risk of death from any cause in women.
Wednesday, January 6, 2010
Breast-feeding may benefit a woman's heart.
Source: AMA Morning Rounds 12/22/09
Breast-feeding may benefit a woman's heart.
Sunday, November 29, 2009
High salt intake directly linked to stroke and cardiovascular disease
Source: BMJ press releases Monday 23 November to Friday 27 November 2009. Available in full at www.bmj.com
(1) High salt intake directly linked to stroke and cardiovascular disease
(Research: Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies)
http://www.bmj.com/cgi/doi/10.1136/bmj.b4336
(Editorial: The case for population-wide salt reduction gets stronge)
http://www.bmj.com/cgi/doi/10.1136/bmj.b4336
High salt intake is associated with significantly greater risk of both stroke and cardiovascular disease, concludes a study published on bmj.com today.
The link between high salt intake and high blood pressure is well established, and it has been suggested that a population-wide reduction in dietary salt intake has the potential to substantially reduce the levels of cardiovascular disease.
The World Health Organization recommended level of salt consumption is 5 g (about one teaspoon) per day at the population level, yet dietary salt intake in most Western countries is close to 10g per day (and much higher in many Eastern European countries).
Collaborative research conducted by Professor Pasquale Strazzullo at the University of Naples, Italy and Professor Francesco Cappuccio at the University of Warwick, UK analysed the results of 13 published studies involving over 170,000 people that directly assessed the relationship between levels of habitual salt intake and rates of stroke and cardiovascular disease.
Differences in study design and quality were taken into account to minimise bias.
Their analysis shows unequivocally that a difference of 5 g a day in habitual salt intake is associated with a 23% difference in the rate of stroke and a 17% difference in the rate of total cardiovascular disease.
Based on these results, the authors estimate that reducing daily salt intake by 5 g at the population level could avert one and a quarter million deaths from stroke and almost three million deaths from cardiovascular disease each year. Furthermore, because of imprecision in measurement of salt intake, these effect sizes are likely to be underestimated, say the authors.
These results support the role of a substantial population reduction in salt intake for the prevention of cardiovascular disease, they conclude.
This study is a useful and welcome addition to the medical literature, and strengthens the case for population-wide salt reduction, says Professor Lawrence Appel from Johns Hopkins University, in an accompanying editorial.
Contacts:
Research: Pasquale Strazzullo, Professor of Medicine, Department of Clinical and Experimental Medicine, "Federico II" ESH Excellence Centre of Hypertension, University of Naples Medical School, Naples, Italy
Email: strazzul@unina.it
Editorial: Lawrence Appel, Professor of Medicine (via Stephanie Desmon, Senior Media Relations Representative), Johns Hopkins University, Baltimore, MD, USA
Email: sdesmon1@jhmi.edu
Monday, March 23, 2009
Depression and antidepressant use linked to sudden cardiac death
New York, NY - A new analysis has found that major depression predicted cardiovascular morbidity and mortality in women participating in the Nurses' Health Study [1]. The hazard ratios were strongest for fatal events and were driven by the association of depression—in particular, antidepressant use—with sudden cardiac death (SCD). Dr William Whang (Columbia University, New York, NY) and colleagues report their findings in the March 17, 2009 issue of the Journal of the American College of Cardiology.
But the authors and accompanying editorialists conclude that, at the present time, the benefits of appropriately prescribed antidepressant use likely outweigh the risk of SCD.
"The absence of proof that antidepressants might cause cardiac events is more relevant than conclusive proof that this effect is absent. Nevertheless, these findings are sufficiently sobering to warrant heightened clinical surveillance and to initiate studies to definitively address this relationship," say Drs Sanjiv M Narayan and Murray B Stein (University of California, San Diego [UCSD]) in an accompanying editorial comment [2].
Whang told heartwire that he believes the biggest clinical implication of this new study "is that management of coronary heart disease risk factors may be especially important among women with depressive symptoms."
Those using antidepressants three times more likely to suffer SCD
Whang et al prospectively studied 63 469 women in the Nurses' Health Study without baseline coronary disease, stroke, or malignancy. They studied depressive symptoms and a proxy variable for clinical depression consisting of severe symptoms and/or antidepressant use and their relationship to cardiovascular events.
Questionnaires in 1992, 1996, and 2000 assessed depressive symptoms, with major depression defined by a validated five-point mental-health-index score (MHI-5) of <53,>
Of the women, 7.9% had MHI-5 scores of <53,>
From 1996 onward, the proxy variable of severe symptoms and/or antidepressant use was most associated with SCD in multivariable models (HR 2.33), and the risk was primarily due to a specific relationship between antidepressant use and SCD (HR 3.34).
Narayan and Stein say the work of Whang et al stands out from previous research of this kind: "[This research] is particularly exciting. The authors should be congratulated for these important data on the etiologic role of depression and its treatment on cardiovascular outcomes in a very large cohort of healthy individuals."
Arrhythmia a possible mechanism, but further study needed
"This surprising results merits scrutiny," the editorialists say. Numerous pharmaceutical agents might contribute to arrhythmic mortality, and in the present study, 61% of subjects were using selective serotonin-reuptake inhibitors (SSRIs), while 39% used other, nonspecified antidepressants.
"Our study raises questions about the mechanism by which depression is associated with sudden cardiac death," Whang told heartwire. "This is not the first study to link risk of SCD to depression. Our study is consistent with prior analyses that have found an association between depressive symptoms and a higher mortality in patients with CHD, and it points to arrhythmia as a possible mechanism for this worse prognosis."
Narayan and Stein say: "It is unclear whether SSRI agents might cause [sudden cardiac arrest]. While cardiac events are well documented with . . . tricyclic antidepressants, evidence for a link with SSRIs is mixed."
"Moreover, it is quite possible that antidepressant use merely indicates that depression is of sufficient severity to merit treatment." It is well established that patients with depression after acute coronary syndrome, for example, are less likely to adhere to their cardiac medication regimens, note the UCSD doctors, although treating the depression improves adherence.
"Clearly, the burden of proof rests on confirming this association. There are abundant data attesting to the safety and efficacy of SSRIs in particular, and a relative paucity showing adverse cardiac effects," they conclude.
Whang et al agree: "Although antidepressant medication use might be a marker of worse depression, its specific association with elevated risk of SCD merits further study."
|
| Narayan reports receiving speaking honoraria or serving as a consultant for St Jude Medical, Boston Scientific, Medtronic, Biosense-Webster, and Cambridge Heart. Stein receives or has received in the past three years research support from Eli Lilly and GlaxoSmithKline and is currently or in the past three years has been a consultant for BrainCells, Bristol-Myers Squibb, Eli Lilly, EPI-Q, Forest Laboratories, Hoffman La-Roche Pharmaceuticals, Integral Health Decisions, Jazz Pharmaceuticals, Johnson & Johnson, Mindsite, Pfizer, Sanofi-Aventis, Sepracor, Transcept Pharmaceuticals, and Virtual Reality Medical Center. |
- Whang W, Kubzansky LD, Kawachi I, et al. Depression and risk of sudden cardiac death and coronary heart disease in women. Results from the Nurses' Health Study. J Am Coll Cardiol 2009; 53:950-958
- Narayan SM and Stein MB. Do depression or antidepressants increase cardiovascular mortality? The absence of proof might be more important than the proof of absence. J Am Coll Cardiol 2009; 53:959-961
- Dryden J. Depression increases risk for heart disease more than genetics or environment [press release]. March 3, 2009. Available at: http://mednews.wustl.edu/news/page/normal/13643.html?emailID=23300.
Large meta-analysis links anger, hostility with CHD risk, particularly in men
London, UK - Anger and hostility were associated with a 19% increase in coronary heart disease (CHD) events in healthy individuals and a 24% increase in risk among those with preexisting CHD, researchers report in the first large, systematic meta-analysis to show significant links between those two mind states and CHD [1].
"The harmful effect of anger and hostility has been widely asserted, but previous reviews have been inconclusive," Dr Yoichi Chida and Dr Andrew Steptoe (both from University College London, UK) write in their review published in the March 17, 2009 issue of the Journal of the American College of Cardiology.
"Intriguingly, the harmful effect of anger and hostility on CHD events in the healthy populations was greater in men than women," the researchers write. In the healthy-population studies, the researchers found a strong association between anger and hostility and CHD in men (HR 1.22, p<0.001),>
"Previous meta-analyses failed to show significant associations of anger and hostility with CHD," Chida told heartwire. Chida added that this report includes several studies published since the last major meta-analytical review.
Chida's review included 21 articles (71 606 individuals) on CHD outcomes in healthy populations and 18 articles (n=8120) of people with preexisting CHD, from studies conducted in Australasia, Europe, and America. Anger and hostility were associated with increased CHD events in the healthy-population studies, with a combined HR of 1.19 (p=0.008), and those emotions were associated with poor prognosis in the population with existing CHD (HR 1.24, p=0.002). In the studies of individuals with baseline CHD, the poor prognosis associated with anger and hostility persisted after researchers fully controlled for basal disease status and treatment, the article states.
Although the body of research investigating the association between anger and hostility and CHD has grown during the past 25 years, several reviews of the literature have produced different findings, possibly because some looked at individual facets of the overall construct, such as hostility alone. Another possible confounder could be the inclusion of cross-sectional, retrospective, and prospective studies in previous reviews, the researchers write in their analysis, which was limited to prospective cohort investigations.
The analysis found that CHD risk appeared to be mediated through high-risk behaviors, with the association between anger/hostility and CHD becoming no longer significant after full adjustment for behavioral factors such as smoking, physical activity, body-mass index, or socioeconomic status.
Small but notable risk
In an accompanying editorial [2], Dr Johan Denollet and Dr Susanne S Pedersen (both from Tilburg University, the Netherlands) point out that while the overall size of the associations between anger and hostility and subsequent CHD reported by Chida et al might seem small, it appears notable when compared with the 11% increased risk associated with von Willebrand factor in the Reykjavik Study [3].
"This meta-analytic review is of high scientific quality and provides us with a reliable estimate of the risk associated with anger/hostility," Denollet told heartwire. "This review has important clinical implications, because it supports the notion that adverse psychological factors do matter in the development and progression of CHD. Moreover, these findings indicate that psychological factors, in this case anger/hostility, start to show their adverse effect after a couple of years, suggesting that these factors are especially of importance in the long run and that more long-term follow-up studies are needed."
Symptoms of anger/hostility should be taken seriously. "Clinicians may consider referring their coronary patients with high levels of anger for behavioral intervention," he said in the interview with heartwire.
Regarding the findings that the association between anger/hostility and CHD appears mediated by lifestyle behaviors and socioeconomic status, Denollet told heartwire, "I think that a number of these unhealthy lifestyles—smoking, overeating—may reflect attempts to downregulate feelings of tension associated with anger/hostility. Socioeconomic status may reflect a vulnerability factor for increased levels of anger/hostility."
One important direction for future research would be the role of emotion-regulation strategies that might moderate the effects of anger and hostility.
"There is some evidence that suppression of anger increases the risk of hypertension and coronary disease and that inhibition of emotion and behavior in general may further increase the risk of stress-related CHD. Future research should more often focus on the interplay between negative emotions and emotion-regulation strategies as a determinant of major coronary events," Denollet said.
"I think we need to be careful to not simply conclude that 'anger is bad for the heart.' After all, anger is a natural emotion that can be very adaptive (eg, as a warning signal), provided that this negative emotion is regulated and used in a socially meaningful and adaptive way," he added.
| Chida receives support from the Kanae Foundation for the Promotion of Medical Science and the Medical Research Council. Steptoe receives support from the British Heart Foundation. Denollet and Pedersen report no disclosures. |
- Chida Y, Steptoe A. The association of anger and hostility with future Coronary Heart Disease. J Am Coll Cardiol 2009; 53:936-946. DOI:10.1016/j.jacc.2008.11.044.
- Denollet J, Pedersen SS. Anger, depression, and anxiety in cardiac patients. J Am Coll Cardiol 2009; 53:947-9.
- Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New Engl J Med 2004; 350:1387-97.
Very low LDL and normal BP result in slowest progression of atherosclerosis
Cleveland, OH - Patients with coronary artery disease (CAD) who reduce LDL cholesterol to very low levels and achieve a normal systolic blood pressure have the slowest progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS), a new study has shown [1]. The findings, according to investigators, support the need for intensive management of global risk in patients with CAD.
"What's happened in recent years with the advent of more potent statins and all the education done around that is that getting people to LDL goal is achieved fairly well," senior investigator Dr Steven Nissen (Cleveland Clinic, OH) told heartwire. "But getting people to dual goals is not done well around the country. We wanted to tell people that there really is some pretty good evidence here that if you get your blood pressure down to normal and your LDL down below 70, this is a disease that can not only be halted, but potentially can even regress."
The results of the study are published in the March 24, 2009 issue of the Journal of the American College of Cardiology.
Seven studies rolled into one
To clarify the relationship between LDL cholesterol and systolic blood pressure and their effects on coronary plaque progression, the researchers, led by Dr Adnan Chhatriwalla (Cleveland Clinic) studied 3437 patients with established CAD enrolled in seven clinical trials. The studies included REVERSAL, CAMELOT, ACTIVATE, ASTEROID, ILLUSTRATE, PERISCOPE, and STRADIVARIUS, a group of trials that investigated statins, acyl coenzyme A:cholesterol acyltransferase (ACAT) and cholesteryl ester transfer protein (CETP) inhibitors, rimonabant, ACE inhibitors, and calcium-channel blockers, among others.
Patients were stratified into four groups based on their average on-treatment LDL-cholesterol levels and systolic blood pressure:
- LDL cholesterol <70 mg/dL and systolic blood pressure <120 mm Hg.
- LDL cholesterol <70 mg/dL and systolic blood pressure >120 mm Hg.
- LDL cholesterol >70 mg/dL and systolic blood pressure <120 mm Hg.
- LDL cholesterol >70 mg/dL and systolic blood pressure >120 mmHg.
Changes in atheroma burden were monitored by IVUS, which was measured at baseline and at 18 to 24 months.
Patients with very low LDL-cholesterol levels and normal systolic blood pressure, group 1, had the least progression in percent atheroma volume (PAV) and total atheroma volume (TAV). In addition, these patients also had less frequent atheroma progression and more frequent regression. In patients with systolic blood pressure >120 mm Hg who still had very low LDL cholesterol levels, group 2, less progression of PAV and TAV was also observed.
"It really makes a big difference if you can get both down," said Nissen. "It's a big payoff for patients if physicians are diligent about getting LDL and blood pressure under control."
Among patients with LDL-cholesterol levels >70 mg/dL, normal systolic blood pressure was associated with no greater reduction in PAV or TAV, suggesting that lipid lowering has a larger impact than blood-pressure control on plaque progression, findings supported by recent clinical trials.
The findings challenge current treatment recommendations for hypertension, noted Nissen, and he recommends treating prehypertensive patients with coronary disease, those with pressures of 120 to 139 mm Hg systolic or 80 to 89 mm Hg diastolic. In the CAMELOT study, he points out, the calcium-channel blocker amlodipine decreased the risk of cardiovascular events in patients with CAD and normal blood pressure, as did the ACE inhibitor enalapril, but to a lesser extent.
"Remember that these are all people who have coronary artery disease," said Nissen. "These are not your typical primary-prevention patients with hypertension. They already have atherosclerotic disease in their coronaries. We think the evidence is pretty strong that if you already have plaques in your coronaries, you really to have a lower blood-pressure target. . . . Our IVUS data suggest that there is opportunity here to help patients."
Nissen admitted that the issue needs to be studied further and that the ongoing AQUARIUS study will assess changes in atherosclerotic disease progression with aliskiren (Tekturna, Novartis) when given in addition to standard therapy in CAD patients with prehypertension.
More data still needed
In an editorial accompanying the published study, Drs Jonathan Tobis and Alice Perlowski (University of California, Los Angeles) write that human and animal data make clear that a combination of aggressive lipid and blood-pressure control are necessary for a maximum attenuation of plaque progression, improved endothelial function, and reduced inflammation caused by oxidative stress [2].
Regarding the treatment of prehypertensive patients, Tobis and Perlowski write that a lack of data has contributed to a delayed acceptance of the need for drug therapy. In addition to AQUARIUS, the ongoing SPRINT, which is comparing intensive blood-pressure control (<120>130 mm Hg who have one additional risk factor, will help answer those questions.
The editorialists note that plaque progression/regression on IVUS is helpful in determining whether or not clinicians are helping their patients, but hard clinical end points are still needed, especially as they are shown to correspond with predictions based on the IVUS surrogates. Until then, "conclusions derived from these trials should be considered inferential, to be used as guides for future trials focused on clinical-outcomes measures," they write.
Asked about the polypill, Nissen told heartwire that he was not an initial fan, but with these and other data, he is starting to warm up to it. "The idea of having something that you go and get for $10 for three months that would control your blood pressure and your lipids, this study makes the case that it might make some sense."
New results about a polypill approach for primary prevention, combining a BP-lowering drug, a statin, and aspirin in a single pill, will be presented at the American College of Cardiology 2009 meeting next week.
| Nissen reports receiving research support from AstraZeneca, Eli Lilly, Pfizer, Takeda, Sankyo, and Sanofi-Aventis and that he donates honoraria, consulting fees, and other payments directly to charity. Chhattriwalla reports no conflicts. |
- Chhatriwalla AK, Nicholls SJ, Wang TH, et al. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol 2009; 53: 1110-1115.
- Tobis JM, Perlowski A. Atheroma volume by intravascular ultrasound as a surrogate for clinical endpoints. J Am Coll Cardiol 2009; 53: 1116-1118.
Meat Intake and Mortality
Meat Intake and Mortality
A Prospective Study of Over Half a Million People
Arch Intern Med. 2009;169(6):562-571.
Background High intakes of red or processed meat may increase the risk of mortality. Our objective was to determine the relations of red, white, and processed meat intakes to risk for total and cause-specific mortality.
Methods The study population included the National Institutes of Health–AARP (formerly known as the American Association of Retired Persons) Diet and Health Study cohort of half a million people aged 50 to 71 years at baseline. Meat intake was estimated from a food frequency questionnaire administered at baseline. Cox proportional hazards regression models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) within quintiles of meat intake. The covariates included in the models were age, education, marital status, family history of cancer (yes/no) (cancer mortality only), race, body mass index, 31-level smoking history, physical activity, energy intake, alcohol intake, vitamin supplement use, fruit consumption, vegetable consumption, and menopausal hormone therapy among women. Main outcome measures included total mortality and deaths due to cancer, cardiovascular disease, injuries and sudden deaths, and all other causes.
Results There were 47 976 male deaths and 23 276 female deaths during 10 years of follow-up. Men and women in the highest vs lowest quintile of red (HR, 1.31 [95% CI, 1.27-1.35], and HR, 1.36 [95% CI, 1.30-1.43], respectively) and processed meat (HR, 1.16 [95% CI, 1.12-1.20], and HR, 1.25 [95% CI, 1.20-1.31], respectively) intakes had elevated risks for overall mortality. Regarding cause-specific mortality, men and women had elevated risks for cancer mortality for red (HR, 1.22 [95% CI, 1.16-1.29], and HR, 1.20 [95% CI, 1.12-1.30], respectively) and processed meat (HR, 1.12 [95% CI, 1.06-1.19], and HR, 1.11 [95% CI 1.04-1.19], respectively) intakes. Furthermore, cardiovascular disease risk was elevated for men and women in the highest quintile of red (HR, 1.27 [95% CI, 1.20-1.35], and HR, 1.50 [95% CI, 1.37-1.65], respectively) and processed meat (HR, 1.09 [95% CI, 1.03-1.15], and HR, 1.38 [95% CI, 1.26-1.51], respectively) intakes. When comparing the highest with the lowest quintile of white meat intake, there was an inverse association for total mortality and cancer mortality, as well as all other deaths for both men and women.
Conclusion Red and processed meat intakes were associated with modest increases in total mortality, cancer mortality, and cardiovascular disease mortality.
Author Affiliations: Nutritional Epidemiology Branch (Drs Sinha, Cross, Leitzmann, and Schatzkin) and Biostatistics Branch (Dr Graubard), Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland.
Thursday, March 19, 2009
Task force revises aspirin guidelines for heart attack, stroke
Task force revises aspirin guidelines for heart attack, stroke
Cardiovascular Business
Wednesday March 18, 2009
The U.S. Preventive Services Task Force has recommended aspirin use for primary prevention of heart attack and stroke in the March 17 issue of the Annals of Internal Medicine, citing its improved specificity over previous guidelines.
The task force found that men between the ages of 45 and 79 should use aspirin to reduce their risk for heart attacks when the benefits outweigh the harms for potential gastrointestinal bleeding. Women between the ages of 55 and 79 should use aspirin to reduce their risk for ischemic stroke when the benefits outweigh the harms for potential gastrointestinal bleeding.
However, the task force was against the use of aspirin for stroke prevention in women younger than 55 years and for MI prevention in men younger than 45 years.
"The task force has taken positive steps to lend clarity to patients and physicians about the value of aspirin for prevention of cardiovascular events," said American College of Preventive Medicine (ACPM) President Mark B. Johnson, MD. "The new guidelines make it clear that physicians, as a matter of routine practice, should be discussing the pros and cons of daily aspirin use with patients in the target groups."
An ACPM-sponsored survey published in the May 2007 edition of the American Journal of Preventive Medicine found a conversation between the patient and physician to be the strongest predictor of appropriate aspirin use, and that only about one in three patients who are at high risk are actually taking daily aspirin. A separate study by the Partnership for Prevention found that 45,000 lives could be saved each year if 90 percent of the target population took a low-dose aspirin every day. The studies led the American Medical Association (AMA) to adopt a policy to increase education among physicians on the importance of appropriate aspirin counseling.
With the release, the UPSTF updates its aspirin recommendations from 2002, which called on clinicians to discuss aspirin use for primary prevention with adults who are at increased risk for cardiovascular disease. The new USPSTF findings actually recommend aspirin use where benefits outweigh the harms, and further define the appropriate age and gender groupings for which aspirin is indicated.
"We think the new guidelines provide another tool in the armamentarium of the physician and the patient for assuring that a discussion about cardiovascular risk and potential aspirin use routinely takes place in the clinical setting," said David Shih, MD, senior director of medical affairs at ACPM.
Last Updated ( Thursday, March 19 2009 )
Thursday, March 5, 2009
adverse clopidogrel and proton-pump inhibitor interaction
More data support adverse clopidogrel and proton-pump inhibitor interaction
March 3, 2009 Michael O'Riordan TheHeart.org
Denver, CO - More evidence published this week suggests that the concomitant use of clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis) and proton-pump inhibitors (PPIs) attenuates the benefits of antiplatelet therapy and increases the risk of future events. Among discharged acute coronary syndrome (ACS) patients prescribed the two drugs, there was an increased risk of adverse clinical outcomes compared with clopidogrel alone, including higher rates of death or rehospitalization for ACS [1].
"I don't think our study changes the guidelines or the recommendations for clopidogrel use after ACS hospitalization," lead investigator Dr P Michael Ho (Denver Veterans Affairs Medical Center, CO) told heartwire, "but it does suggest, along with other studies, that proton-pump inhibitors shouldn't be prescribed prophylactically just because the patient is on aspirin and clopidogrel. Given the accumulating evidence, this study suggests that unless there is a clear indication for the PPI medication, there might be other stomach medications that patients can take."
The results of the study are published in the March 4, 2009 issue of the Journal of the American Medical Association.FDA issued an early communication about safety review
Clopidogrel is a prodrug converted in the liver to its active form by cytochrome P450 isoenzymes, with P450 2C19 playing a particularly important role. There is evidence suggesting that various PPIs can inhibit P450 2C19, which would alter the effectiveness of clopidogrel and potentially lead to an increased risk of adverse cardiovascular outcomes. As noted by the investigators, many patients treated with clopidogrel and aspirin following ACS are also treated with PPIs to reduce the risk of gastrointestinal bleeding with dual antiplatelet therapy.
In January, the Food and Administration (FDA) announced it was continuing to study the effectiveness of clopidogrel in patients taking other medications, particularly PPIs, as well as in those with genetic variants linked with clopidogrel resistance. Despite the early communication from the FDA, the existing data were insufficient to make firm recommendations, leading investigators to analyze the interaction in a large cohort of Veterans Affairs patients.
In this retrospective cohort study, 8205 patients with ACS taking clopidogrel after discharge from the hospital between 2003 and 2006 were identified. Of these patients, 64% were prescribed a PPI at discharge or during follow-up, while 36% were not prescribed a PPI. Those prescribed a PPI tended to be older and have more comorbid disease, including higher rates of diabetes, prior MI, previous CABG surgery, peripheral vascular disease, and lung and renal disease.
Concomitant use of clopidogrel and a PPI was associated with a 25% greater risk of death or rehospitalization for ACS, the primary end point in this analysis. Individual end points, including rehospitalization for ACS and revascularization procedures, were also significantly increased with the combination, although all-cause mortality was not significantly different between the two treatment regimens. Adverse outcomes following hospital discharge for ACS
Various sensitivity analyses examining time periods of use, as well as a nested case-control analysis, confirmed the findings and suggested it was the interaction of the medications responsible for the increased risk. The increased risk of an adverse outcome associated with the use of clopidogrel and PPI remained statistically significant after researchers excluded those with a history of gastrointestinal bleeding prior to hospitalization for ACS, those who had a bleeding event during hospitalization, and those prescribed an H2-antagonist.
Speaking with heartwire, Ho noted that the risk appears primarily due to recurrent hospitalization for ACS, which is consistent with mechanistic studies suggesting an increased prothrombotic state due to the inhibition of platelet activity with clopidogrel and PPIs. He noted that 8% of patients in this study had a previous history of gastrointestinal bleeding, while 25% had an in-hospital bleed or during follow-up, making them eligible for a PPI. Still, with 64% prescribed a PPI in this study, "it suggests there are a large number of patients prescribed the drug prophylactically," said Ho.
Regarding the lack of mortality risk associated with the interaction, Ho said that researchers had access only to all-cause mortality data and that more detailed causes of death might show a signal, particularly with cardiovascular death.
The researchers also note that 60% of patients taking a PPI were prescribed omeprazole, a drug available over the counter since 2003, and that there was a strong association between its use with clopidogrel and adverse clinical outcomes. Overall, said Ho, the findings highlight the importance of a drug interaction not observed in large clinical trials and suggest that drug surveillance is critical after drug approval to monitor unintended side effects and interactions.
SCAI issues a statement
In light of the findings, the Society for Cardiovascular Angiography and Interventions (SCAI) issued a statement that patients prescribed clopidogrel and other antiplatelet medications after undergoing interventional cardiology procedures should continue taking the drugs unless told to stop by their physician.
An expert consensus document developed by the American College of Cardiology, American Heart Association, and American College of Gastroenterology and published in 2008 notes that PPIs should be the mainstay of treatment and prevention of gastrointestinal ulcers and bleeding in patients on antiplatelet therapy who are at increased risk for the gastrointestinal complications. High-risk patients who might benefit from a PPI include patients with a history of ulcer disease, gastrointestinal bleeding, a need for dual antiplatelet therapy, or an indication for warfarin or other anticoagulants, according to the report.
SCAI recommends physicians continue prescribing dual antiplatelet therapy after stent implantation according to the guidelines and prescribe a PPI medication when there is a clinical indication for it.
Source
Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301:937-944.
Wednesday, February 4, 2009
High resting pulse increases risk of MI, coronary death in women
Heartwire
Clinical cardiology
High resting pulse increases risk of MI, coronary death in women
February 4, 2009
Washington, DC - A high resting heart rate is associated with an increased risk of MI or coronary death in females, a new analysis from the Women's Health Initiative (WHI) shows [1]. Dr Judith Hsia (AstraZeneca, Wilmington, DE, who was at George Washington University when this research was done) and colleagues report the findings online February 3, 2009 in BMJ.
"Multiple studies in men have previously shown that a high heart rate, after adjustment for other potential confounders such as blood pressure and cholesterol, is associated with an increased risk of heart attack and coronary death," Hsia explained to heartwire. "But this is the first demonstration in women that having a high heart rate increases this risk."
She points out that it was only women in the highest quintile (with a heart rate of 76 bpm or higher) who had a significantly increased risk and that there was no relationship between high resting pulse and risk of stroke in this cohort.
In terms of implications for doctors, Hsia says, as physicians already check resting pulse as part of their global cardiovascular risk assessment, "they may just consider this in addition to the factors they already use when deciding how aggressively people need to be managed. If, for example, you have a patient who is reluctant to take something for their blood pressure or cholesterol, maybe they should think again if they have a high resting heart rate."
Association present across ethnic groups, strongest in younger women
In their analysis, Hsia et al identified 2281 women with MI or coronary death and 1877 with stroke over a mean of 7.8 years of follow-up among 129 135 postmenopausal women in the WHI with no history of cardiovascular events. They evaluated associations between resting heart rate and cardiovascular events in Cox regression models adjusted for multiple covariates. Hsia points out that the WHI is one of the few studies to have detailed information on physical activity, which was also adjusted for.
Higher resting heart rate was independently associated with a 26% increased risk of coronary events (hazard ratio 1.26 for highest quintile [>76 bpm] vs lowest quintile [<62 bpm]; p=0.001), but not with stroke (HR 1.01).
The relation between resting pulse and risk of coronary events was stronger in younger postmenopausal women (aged 50 to 64) than in older ones (65 and over), and heart rate was similarly predictive for coronary events across all ethnic groups included in the study, Hsia said.
What's attractive about this analysis is that heart rate is such a low-tech assessment.
The strength of this association, from lowest to highest quintile of heart rate, is less than the association with cigarette smoking or diabetes mellitus, Hsia and colleagues add, but they say it "might be large enough to be clinically meaningful," and they stress that it is independent of physical activity.
"We don't know exactly why this higher heart rate is associated with increased heart-attack risk," Hsia told heartwire. "Heart rate is thought to reflect a balance between the adrenaline side of the system and the vagal side, so it may be that the 'thermostat' is set on the high side for adrenaline in those women who have a higher heart rate.
"What's attractive about this analysis is that heart rate is such a low-tech assessment" compared with more elaborate, time-consuming, and expensive methods to assess autonomic tone, she concludes.
Source
Hsia J, Larson JC, Ockene JK, et al. Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ 2009; DOI:10.1136/bmj.b219. Available at: http://www.bmj.com.